These exploratory subpopulation findings are hypothesis-generating and do not alter the regulatory path for fasedienol. The next catalyst is the design and outcome of a potential Phase 3 trial in the very severe subpopulation, which has not been announced. Monitor for any regulatory feedback or trial initiation.
Price Chart
Executive Summary
Vistagen presented positive exploratory data at Psych Congress 2026 showing a potential efficacy signal for fasedienol in patients with very severe social anxiety disorder (LSAS >=95). The post-hoc analysis of PALISADE-4 Phase 3 and a prespecified Phase 2a repeat-dose study both showed statistically significant improvements in anxiety symptoms, though the Phase 3 trial missed its primary endpoint in the overall population. These subpopulation findings are exploratory and do not change the regulatory path for fasedienol.
Key Facts
- Exploratory data presented at Psych Congress 2026 for fasedienol in very severe social anxiety disorder (LSAS >=95)
- Post-hoc analysis of PALISADE-4 Phase 3 showed statistically significant benefit on average SUDS scores in very severe subpopulation, though the study missed its primary endpoint in the total population
- Prespecified analysis of Phase 2a repeat-dose study showed statistically significant improvement after a single dose and greater numerical improvement after a second dose
- No serious drug-related safety signals identified
- Fasedienol is an intranasal pherine product candidate for acute treatment of social anxiety disorder
Financial Impact
No financial figures disclosed; exploratory data only
Risk Factors
- PALISADE-4 Phase 3 failed its primary endpoint in the total population, raising uncertainty about fasedienol's overall efficacy
- Subpopulation analyses are exploratory and post-hoc; results may not replicate in a dedicated trial
- No timeline or commitment to a new Phase 3 trial in very severe SAD has been provided
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3368189 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 18d ago | 8-K | $0.2300 $0.2000 | ▼ −13.04% | ▼ −11.55% | $0.1740 (−24.35%) |
Sep 25, 2026 4w ago | 8-K | $0.2700 $0.2800 | ▲ +3.70% | ▲ +3.93% | $0.1740 (−35.56%) |
Sep 24, 2026 4w ago | 8-K | $0.2950 $0.2826 | ▼ −4.20% | ▼ −3.79% | $0.1740 (−41.02%) |
Sep 24, 2026 4w ago | Press Release | $0.2950 $0.2826 | ▼ −4.20% | ▼ −3.79% | $0.1740 (−41.02%) |
Aug 14, 2026 10w ago | 8-K | $0.2676 $0.2440 | ▲ +8.82% | ▲ +7.45% | $0.1740 (+34.98%) |
Aug 14, 2026 10w ago | Press Release | $0.2676 $0.2440 | ▼ −8.82% | ▼ −7.45% | $0.1740 (−34.98%) |
Jul 31, 2026 12w ago | 8-K | $0.2410 $0.2876 | ▲ +19.34% | ▲ +15.82% | $0.1740 (−27.80%) |
Jun 30, 2026 17w ago | 8-K | $0.2260 $0.2458 | ▼ −8.76% | ▼ −8.16% | $0.1740 (+23.01%) |
Jun 17, 2026 18w ago | 8-K | $0.6702 $0.6166 | ▼ −8.00% | ▼ −6.33% | $0.1740 (−74.04%) |
Jun 15, 2026 19w ago | 8-K | $0.6900 $0.6323 | ▼ −8.36% | ▼ −6.13% | $0.1740 (−74.78%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers